[Federal Register Volume 64, Number 140 (Thursday, July 22, 1999)]
[Notices]
[Pages 39514-39515]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-18688]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 99D-2145]
International Cooperation on Harmonisation of Technical
Requirements for Registration of Veterinary Medicinal Products (VICH);
VICH GL11 Draft Guidance on Impurities in New Veterinary Medicinal
Products; Availability; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability for comment of a draft guidance developed by the
International Cooperation on Harmonisation of Technical Requirements
for Registration of Veterinary Medicinal Products (VICH). This VICH
GL11 draft guidance for industry entitled ``Impurities in New
Veterinary Medicinal Products'' provides guidance recommendations for
applications for marketing authorizations on the content and
qualification of impurities in new veterinary medicinal products
produced from chemically synthesized new active substances not
previously registered in a member state.
DATES: Submit written comments by August 23, 1999; FDA must receive
comments before the deadline in order to ensure their consideration at
the next VICH committee meeting, but the agency will accept comments
after the deadline.
ADDRESSES: Submit written comments to the Dockets Management Branch
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Comments should be identified with the full title
of the draft guidance and the docket number found in brackets in the
heading of this document.
Copies of the draft guidance entitled ``Impurities in New
Veterinary Medicinal Products'' may be obtained on the Internet from
the CVM home page at ``http://www.fda.gov/cvm/fda/TOCs/
guideline.html''. Persons without Internet access may submit written
requests for single copies of the draft guidance to the Communications
Staff (HFV-12), Center for Veterinary Medicine, Food and Drug
Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-
addressed adhesive label to assist that office in processing your
requests.
FOR FURTHER INFORMATION CONTACT:
Regarding the VICH: Sharon R. Thompson, Center for Veterinary
Medicine (HFV-3), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301-594-1798, e-mail sthompso@cvm.fda.gov''.
Regarding the draft guidance: Kevin J. Greenlees, Center for
Veterinary Medicine (HFV-150), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-6977, e-mail
kgreenle@cvm.fda.gov''.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, many important initiatives have been undertaken by
regulatory authorities, industry associations, and individual sponsors
to promote the international harmonization of regulatory requirements.
FDA has participated in efforts to enhance harmonization and has
expressed its commitment to seeking scientifically based harmonized
technical requirements for the development of pharmaceutical products.
One of the goals of harmonization is to identify and reduce the
differences in technical requirements for drug development among
regulatory agencies in different countries.
FDA has actively participated in the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) for several years to develop
harmonized technical requirements for the registration of human
pharmaceutical products among the European Union, Japan, and the United
States. The VICH is a parallel initiative for veterinary medicinal
products. The VICH is concerned with developing harmonized technical
requirements for the registration of veterinary medicinal products in
the European Union, Japan, and the United States, and includes input
from both regulatory and industry representatives.
The VICH meetings are held under the auspices of the Office
International des Epizooties. The VICH Steering Committee is composed
of member representatives from the European Commission; the European
Medicines Evaluation Agency; the European Federation of Animal Health;
the U.S. FDA; the U.S. Department of Agriculture; the Animal Health
Institute; the Japanese Veterinary Pharmaceutical Association; and the
Japanese Ministry of Agriculture, Forestry, and Fisheries.
Four observers are eligible to participate in the VICH Steering
Committee: One representative from the Government of Australia/ New
Zealand, one representative from the industry in Australia/ New
Zealand, one representative from MERCOSUR (Argentina, Brazil, Uruguay,
and Paraguay), and one representative from Federacion Latino-Americana
de la Industria para la Salud Animal. The VICH Secretariat, which
coordinates the preparation of documentation, is provided by the
Confederation Mondiale de L'Industrie de la Sante Animale (COMISA). A
COMISA representative participates in the VICH Steering Committee
meetings.
At a meeting held on October 20 through 22, l998, the VICH Steering
Committee agreed that the draft guidance entitled ``Impurities in New
Veterinary Medicinal Products'' should be made available for public
comment. Comments will be considered by FDA and the VICH Quality
Working Group. Ultimately, FDA intends to adopt the VICH Steering
Committee's final guidance and publish it as a future guidance.
This draft guidance, developed under the VICH process, has been
revised to conform to FDA's good guidance practices regulations (62 FR
8961, February 27, l997) . For example, the document has been
designated as a draft ``guidance'' rather than a draft ``guideline.''
Since guidance documents are not binding, mandatory words such as
``must,'' ``shall,'' and ``will'' in the original VICH document have
been substituted with ``should,'' unless the reference is to a
statutory or regulatory requirement. Additionally, the term(s)
``veterinary medicinal products'' and ``veterinary pharmaceutical
products'' may require revision to be consistent with product terms
used in other VICH guidance documents.
This draft guidance represents the agency's current thinking on
impurities
[[Page 39515]]
in new veterinary medicinal products. The document does not create or
confer any rights for or on any person and will not operate to bind FDA
or the public. Alternate approaches may be used if they satisfy the
requirements of applicable statutes, regulations, or both.
II. Comments
Interested persons should submit written comments on or before
August 23, 1999, to the Dockets Management Branch (address above)
regarding this draft guidance. Two copies of any comments are to be
submitted, except that individuals may submit one copy. Comments should
be identified with the docket number found
in brackets in the heading of this document. A copy of the document and
received comments are available for public examination in the Dockets
Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
Dated: July 15, 1999
Margaret M. Dotzel,
Acting Associate Commissioner for Policy.
[FR Doc. 99-18688 Filed 7-21-99; 8:45 am]
BILLING CODE 4160-01-F
